Unknown

Dataset Information

Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells.


ABSTRACT:

Background

Metabolic disorders are associated with increased incidence, aggressive phenotype and poor outcome of breast cancer (BC) patients. For instance, hyperinsulinemia is an independent risk factor for BC and the insulin/insulin receptor (IR) axis is involved in BC growth and metastasis. Of note, the anti-diabetic metformin may be considered in comprehensive therapeutic approaches in BC on the basis of its antiproliferative effects obtained in diverse pre-clinical and clinical studies.

Methods

Bioinformatics analysis were performed using the information provided by The Invasive Breast Cancer Cohort of The Cancer Genome Atlas (TCGA) project. The naturally immortalized BC cell line, named BCAHC-1, as well as cancer-associated fibroblasts (CAFs) derived from BC patients we

SUBMITTER: Scordamaglia D 

PROVIDER: S-EPMC9172136 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature